Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oncorine + Camrelizumab + Nab-paclitaxel in Melanoma Liver Metastases
NCT05664139Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Feb 2023
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
01
Overview
Phase 2, open-label, single-arm trial of Oncorine in Malignant Melanoma (MM), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective Tumor Response Rate at 1 year. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
Oncorine
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT05664139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05664139.